
Oncogene Cancer Research
Apr 5, 2025, 11:53
Biomarker testing means being put on the right treatment at the right time – Oncogene Cancer Research
Oncogene Cancer Research shared a post on LinkedIn:
“Our co-founder Jan Clark’s daughter Amy was diagnosed with stage 4 lung cancer at just 20 years old. Amy was told she would need to go in chemo but a biomarker test revealed an ALK-positive mutation.
This meant Amy went on to take a targeted therapy – an oral medication that inhibits her cancer and is much more tolerable. Five years on, Amy is still on that treatment, works full-time and has a full life.
Here Jan explains more.
Biomarker testing means being put on the right treatment at the right time. Please help us create more awareness of biomarker testing by sharing.
Thank you to Lung Cancer Europe for the creation of this film.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 5, 2025, 16:02
Apr 5, 2025, 15:21
Apr 5, 2025, 15:16
Apr 5, 2025, 15:04